Evidence map›Paper›PMID 40208755›Full record

ArticlePharmacogenomics

Pharmacogenetics to optimize immunosuppressant therapy in systemic lupus erythematosus: a scoping review.

Alim Khodimul Rahmat, Irmasari, Zahrotun Nafiah, Zullies Ikawati

Abstract readScoping Review
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacogenomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alim Khodimul RahmatDoctor's Program in Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia.ORCID 0009-0000-8710-2461
IrmasariMaster's Program in Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia.ORCID 0009-0006-8166-1549
Zahrotun NafiahMaster's Program in Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia.ORCID 0000-0002-1188-2243
Zullies IkawatiDepartment of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia.ORCID 0000-0002-4812-055X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic lupus erythematosus (SLE) is a complex autoimmune disease requiring immunosuppressive medications to control symptoms and prevent organ damage. This review explores the influence of genetic polymorphisms on the pharmacokinetics and therapeutic responses of immunosuppressants in SLE. A total of 37 studies were reviewed, focusing on mycophenolic acid, tacrolimus, azathioprine, glucocorticoids, and cyclophosphamide. Genetic variants in

Indexed as

Immunosuppressive AgentsLupus Erythematosus, SystemicPharmacogeneticsHumansMultidrug Resistance-Associated Protein 2Polymorphism, GeneticABCC2 protein, humanImmunosuppressive AgentsMultidrug Resistance-Associated Protein 2genetic polymorphismsimmunosuppressantspharmacogeneticsprecision medicineSystemic lupus erythematosus

Identifiers

PMID40208755
PMCPMC12128666

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.